Thermo Fisher Scientific Inc (TMO) Stock Analysis

Verdict: BUY

Q2 earnings beat signals the end of the bioprocessing destocking cycle, but aggressive insider selling and DCF premiums limit near-term upside.

Investment score: 68/100

Analysis as of 2026-07-23

Is Thermo Fisher Scientific Inc stock worth reviewing? AI model thesis

The model identifies TMO as a high-quality compounder in a recovery phase, but current technical overextension suggests holding for a better entry point.

7-factor investment score

Valuation: 60/100 (weight 20%)
Financial Health: 75/100 (weight 15%)
Technical Momentum: 80/100 (weight 15%)
Earnings Quality: 85/100 (weight 15%)
Insider Sentiment: 30/100 (weight 10%)
Analyst Consensus: 75/100 (weight 10%)
Risk-Adjusted Return: 70/100 (weight 15%)

Thermo Fisher Scientific Inc opportunities and risks

What speaks for TMO

End of Bioprocessing Destocking

What speaks against TMO

Exposure to Bio-Pharma Capital Spending Cycles

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
TMO	30.9x	4.6x	23.1x	40.4%	15.1%	3.4%
DHR	36.3x	5.3x	24.0x	60.7%	14.9%	4.1%
A	27.8x	5.4x	20.8x	53.0%	19.6%	3.2%
WAT	48.2x	6.6x	32.3x	55.0%	11.9%	1.1%
IQV	25.2x	2.1x	13.7x	26.1%	8.3%	7.4%
ILMN	35.4x	6.8x	21.8x	67.1%	19.4%	3.3%
Peer median	35.4x	5.4x	21.8x	55.0%	14.9%	3.3%

Frequently asked questions about Thermo Fisher Scientific Inc (TMO)

Is TMO stock a good investment?

The cached TradeMates AI model rates Thermo Fisher Scientific Inc as BUY with an investment score of 68/100. The model identifies TMO as a high-quality compounder in a recovery phase, but current technical overextension suggests holding for a better entry point. This is algorithmic model output, not personal investment advice.

Is TMO stock a buy?

The TradeMates model verdict for TMO is BUY with an investment score of 68/100. Treat this as a model signal to review, not a personal buy recommendation.